Hello Everyone. I know it's been a while since I checked in but there has been a confluence of events-- I blog on the NY Giants in season -- so that takes up a lot of my time this time of year. As well of course I just became thoroughly disgusted with the market and found myself uninterested in buying anything.
I went to some high yield names and I made some interesting purchases which I will go through with you all at some length at some time. I'll have to go back to the old threads to see which members of the ET Portfolio I still own. For better or worse there still are quite a few like CIGX & UNIS & CRI.
Today I purchased a stock I have been following technically- AUXL.
I like this Bio name, they have an existing product that is for gnarled curved fingers from short tendons. This product may have a second application for curved penises.
A report I spotted from some house mentioned some Bio's that might surprise to the upside. ALXN was one, but that's no surprise they are ripping to a new high. BMRN was one, no surprise here either been up all year... but AUXL was on that list too so I started digging because it's DOWN from prior highs..
Now if you've watched any amount of Porno in your life you've seen these guys with the big hook in the Penis... it's not a good look. The poor girls squirm, that head is poking at angles that are best left to a discreet self touch. And the guys are way embarrassed when they whip it out. Peyronie's disease is no joke.
Auxilium's other target Dupuytren's Contracture, is a condition that makes the tendons of the hand thicken and shorten, causing the fingers to curve inward. Auxilium started marketing Xiaflex for that painful problem that my Grandmother had in March 2010.
For whatever reason the launch bombed a bit. In August Auxilium lowered its forecast for 2011 U.S. revenue from the drug. It now expects $45 million to $50 million, down from its previous estimate of $50 million to $60 million. A Ten mil hit. Yikes.
The stk was $20 and went on to bottom out at $14. The shortfall for the future rather obscured the fact that second-quarter revenue from Xiaflex rose to $15.4 million from $3.1 million a year ago. So it's moving the right direction UP. The Co oversold it to investors but now that news is priced in we are in on the ground floor today @ $16 and change and hopefully we can guide up from here on Xiaflex for fingers WHILE ALSO INTRODUCING THE CURVED PENIS ANGLE that no one is taking into account at this time.
Lets let a Citi analyst take it from here:
Shares of Auxilium Pharmaceuticals Inc. offer an attractive risk/reward profile due in part to the drugmaker's development of a potential treatment for Peyronie's disease, according to a Citi analyst.
Dr. Lucy Lu upgraded the stock to "Buy/speculative" from "Hold/speculative" and raised a price target on the shares to $25 from $22.
Lu said most medical literature on Peyronie's disease comes from U.S. physicians and reflects large patient numbers and unmet need. The analyst also said Auxilium's late-stage study of the Xiaflex for that disease will likely be successfully after the drug showed promising results in a mid-stage study. She estimates that U.S. sales of Xiaflex as a Peyronie's disease treatment could reach $124 million by 2015.
>>>> Well if at earnings time management could explain away the $10 mil shortfall for the curved fingers and perhaps highlight the new target for the curved penis, a possible $120 mil plus add for Xiaflex... then thing's get interesting from an M&A point of view.
The stock price should climb back to that $20 mark as we approach Halloween's earnings. Then on the good news we will cruise through $22 towards that $25 level and maybe higher. BUY AUXL. ~stoney
I went to some high yield names and I made some interesting purchases which I will go through with you all at some length at some time. I'll have to go back to the old threads to see which members of the ET Portfolio I still own. For better or worse there still are quite a few like CIGX & UNIS & CRI.
Today I purchased a stock I have been following technically- AUXL.
I like this Bio name, they have an existing product that is for gnarled curved fingers from short tendons. This product may have a second application for curved penises.
A report I spotted from some house mentioned some Bio's that might surprise to the upside. ALXN was one, but that's no surprise they are ripping to a new high. BMRN was one, no surprise here either been up all year... but AUXL was on that list too so I started digging because it's DOWN from prior highs..
Now if you've watched any amount of Porno in your life you've seen these guys with the big hook in the Penis... it's not a good look. The poor girls squirm, that head is poking at angles that are best left to a discreet self touch. And the guys are way embarrassed when they whip it out. Peyronie's disease is no joke.
Auxilium's other target Dupuytren's Contracture, is a condition that makes the tendons of the hand thicken and shorten, causing the fingers to curve inward. Auxilium started marketing Xiaflex for that painful problem that my Grandmother had in March 2010.
For whatever reason the launch bombed a bit. In August Auxilium lowered its forecast for 2011 U.S. revenue from the drug. It now expects $45 million to $50 million, down from its previous estimate of $50 million to $60 million. A Ten mil hit. Yikes.
The stk was $20 and went on to bottom out at $14. The shortfall for the future rather obscured the fact that second-quarter revenue from Xiaflex rose to $15.4 million from $3.1 million a year ago. So it's moving the right direction UP. The Co oversold it to investors but now that news is priced in we are in on the ground floor today @ $16 and change and hopefully we can guide up from here on Xiaflex for fingers WHILE ALSO INTRODUCING THE CURVED PENIS ANGLE that no one is taking into account at this time.
Lets let a Citi analyst take it from here:
Shares of Auxilium Pharmaceuticals Inc. offer an attractive risk/reward profile due in part to the drugmaker's development of a potential treatment for Peyronie's disease, according to a Citi analyst.
Dr. Lucy Lu upgraded the stock to "Buy/speculative" from "Hold/speculative" and raised a price target on the shares to $25 from $22.
Lu said most medical literature on Peyronie's disease comes from U.S. physicians and reflects large patient numbers and unmet need. The analyst also said Auxilium's late-stage study of the Xiaflex for that disease will likely be successfully after the drug showed promising results in a mid-stage study. She estimates that U.S. sales of Xiaflex as a Peyronie's disease treatment could reach $124 million by 2015.
>>>> Well if at earnings time management could explain away the $10 mil shortfall for the curved fingers and perhaps highlight the new target for the curved penis, a possible $120 mil plus add for Xiaflex... then thing's get interesting from an M&A point of view.
The stock price should climb back to that $20 mark as we approach Halloween's earnings. Then on the good news we will cruise through $22 towards that $25 level and maybe higher. BUY AUXL. ~stoney
